ArticleScience progress
Case series: Clinical management strategies of pediatric clonazepam poisoning informed by pharmacokinetics.
Article in Science progress. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aimed to investigate the clinical manifestations of pediatric clonazepam poisoning and to analyze treatment strategies based on its pharmacokinetic characteristics, thereby providing evidence for the clinical management of such cases. A retrospective analysis was conducted on four pediatric patients with clonazepam overdose admitted to our hospital between January 1 and December 31, 2024. Clinical data, including demographic information, clinical manifestations, treatment procedures, and outcomes, were collected and analyzed. Rescue strategies were evaluated in conjunction with the pharmacokinetic properties of clonazepam. All four children presented with varying degrees of dizziness, vomiting, and ataxia following clonazepam ingestion. Gastric lavage was promptly performed in all cases upon hospital admission. Cases 1 and 3 received the specific antidote flumazenil, while cases 1 and 2 underwent hemoperfusion and combined hemoperfusion-continuous venovenous hemofiltration therapy, respectively. All cases achieved complete recovery. Notably, in the two cases treated with hemoperfusion, plasma clonazepam concentrations declined more rapidly than the theoretical elimination time, suggesting that extracorporeal blood purification may facilitate drug clearance in cases of high-dose poisoning. Pediatric clonazepam poisoning is primarily characterized by dose-dependent central nervous system depression. In cases involving large doses or multiple drug overdoses, hemoperfusion may be considered on a case-by-case basis to help reduce plasma drug concentrations; however, further studies are required to confirm its clinical efficacy. Additionally, greater attention to adolescent mental health-particularly during puberty-and enhanced education on medication safety are essential to prevent such poisoning incidents.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.